Stock A195940 HK INNO.N CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News HK inno.N Corporation

Equities

A195940

KR7195940002

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
36,000 KRW -0.83% Intraday chart for HK inno.N Corporation -4.00% -19.01%
Jun. 19 IMBiologics Signs $964 Million Licensing Deal for Autoimmune Treatments MT
Apr. 04 Protium Science Co.,Ltd. announced that it has received KRW 2 billion in funding from HK inno.N Corporation CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
IMBiologics Signs $964 Million Licensing Deal for Autoimmune Treatments
MT
Protium Science Co.,Ltd. announced that it has received KRW 2 billion in funding from HK inno.N Corporation
CI
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada
CI
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation
CI
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
CI
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
CI
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million.
CI
Indian Indices Close in the Red Midweek; Shree Cement Slides 4%
MT
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
CI
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets
MT
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation
CI
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China
MT
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors
CI
HK inno.N Corporation announces an Equity Buyback for KRW 24,200 million worth of its shares.
CI
HK inno.N Corporation authorizes a Buyback Plan.
CI
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio
MT
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021
MT
HK inno.N Enters License Agreement for Gastroesophageal Reflux Drug in the US
MT
HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index
CI
HK inno.N Corporation has completed an IPO in the amount of KRW 596.903 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A195940 Stock
  4. News HK inno.N Corporation